NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017

Restricted access

The prognosis for patients with newly diagnosed acute lymphoblastic leukemia (ALL) has improved with the use of more intensive chemotherapy regimens, tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation. However, the management of relapsed or refractory (R/R) ALL remains challenging and prognosis is poor. The NCCN Guidelines for ALL provide recommendations on standard treatment approaches based on current evidence. These NCCN Guidelines Insights summarize treatment recommendations for R/R ALL and highlight important updates, and provide a summary of the panel's discussion and underlying data supporting the most recent recommendations for R/R ALL management.

Provided content development and/or authorship assistance.

Supplementary Materials

    • Supplemental Material (PDF 219 KB)
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1864 1864 129
PDF Downloads 536 536 54
EPUB Downloads 0 0 0